Bernstein raised the firm’s price target on Zimmer Biomet (ZBH) to $99 from $97 and keeps a Market Perform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet downgraded to Sell from Neutral at Goldman Sachs
- Zimmer Biomet: Buy Rating Driven by Discounted Valuation, Lowered Expectations, and Execution Upside
- Zimmer Biomet downgraded to Market Perform from Outperform at Raymond James
- Evercore ISI upgrades four, downgrades six in MedTech and Tools
- Zimmer Biomet upgraded to Outperform from In Line at Evercore ISI